Methods and systems for analyzing semen
A non-invasive semen analysis method using gene and protein expression in semen samples addresses the invasive nature of current sperm detection, enabling accurate diagnosis and treatment guidance for infertility.
Patent Information
- Application Number
- PCT/US2025/020051
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-23
- Filing Date
- 2025-03-14
- Publication Date
- 2025-09-18
AI Technical Summary
Current methods for determining the presence of sperm or sperm precursors in male subjects are invasive and costly, particularly for those with azoospermia, necessitating a non-invasive and more convenient approach.
A non-invasive method for analyzing semen samples by measuring the expression levels of specific genes or proteins using PCR and flow cytometry to detect the presence, type, and stage of germ cells, including sperm precursors, which reflect the testicular profile.
Enables accurate detection of sperm and immature germ cells in semen, facilitating non-invasive diagnosis of infertility, monitoring fertility treatments, and guiding procedures like TESE and IVF, reducing the need for invasive surgical tests.
Smart Images

Figure US2025020051_18092025_PF_FP_ABST
Abstract
Description
[0001] METHODS AND SYSTEMS FOR ANALYZING SEMEN
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority to U.S. Provisional Patent Application Nos. 63 / 565,928 filed March 15, 2024 and 63 / 651,150 filed on May 23, 2024. The disclosure of the prior applications are considered part of the disclosure of this application and are incorporated herein by reference in their entirety.
[0004] BACKGROUND
[0005] The present disclosure generally relates to methods of analyzing a semen sample. The methods comprise various applications in the medical field, including for diagnosis and prognosis of one or more conditions in a subject. In some cases, the condition may comprise naturally-occurring infertility' or a sub-category thereof. In some cases, the condition may comprise induced infertility (e.g., in response to a male contraceptive or chemotherapy). In some cases, the methods may comprise non-invasive diagnostic tests for infertility. In some cases, the methods may be used to monitor approaches to treat infertility. In some cases, the methods may be used to predict the presence of sperm or sperm precursors in testes that can be used for in-vitro fertilization (IVF).
[0006] SUMMARY
[0007] Infertility is an important condition frequently affecting couples and leading to various issues including reduced quality of life, dissatisfaction, and other problems associated with the lack of ability to conceive a child. In many cases, sperm may be absent from a semen sample of a male subject. Further in some cases, even though sperm may not be present in the semen sample, sperm may be available in an “upstream organ” of the male subject, such as the testes of the subject. Among the approaches used to further study, diagnose, and help such male subjects fertilize an egg of a female partner is to surgically test the testis of the male subject to determine the presence or absence of sperm. In case sperm or the precursor to sperm (called a “spermatid”) is available in the testis, such sperm or precursor thereof may be extracted and used to fertilize an egg of the female partner using a variety of methods, which are further elaborated on herein. However, the current methods to achieve this are surgical and / or invasive, as well as costly. There is a need for a more convenient, non-invasive, and less harmful method to accomplish this purpose. The non-invasive methods described herein can be used as an indicator or predictive test to determine whether the testis of an infertile subject has sperm. Such non-invasive tests may further have various other applications, which are also provided herein.
[0008] Provided herein is a non-invasive method to infer the type and nature of the germ cells in the testis. In particular, this method accomplishes this by analyzing cells in the semen or a sample comprising semen. The profile of germ cells in the semen reflect the profile of germ cells in the testis since a proportion of all the stages of germ cells in the testis leave the testis and go to the epididymis where they become part of semen upon ejaculation. The method may comprise applications for diagnosing fertility or a type thereof. The method may also have various other applications. For example, the method may be used to identify the presence, absence, type, stage of development, or other features of one or more cell types in a semen sample. As described herein, the method can also be used to (i) monitor the action of fertility drugs, (ii) diagnose a loss of sperm because of a physical block of their exit from the testis (called obstructive azoospermia), and (iii) monitor the action male contraceptives designed to temporarily block fertility. In some embodiments, the method may comprise a genetic test.
[0009] In an aspect, provided herein is a method of semen analysis, comprising (a) measuring the expression level of one or more genes or proteins in a semen sample; and (b) predicting or determining the presence, absence, type, or stage of one or more of immature germ cells or other cell types in the semen, based on the expression of specific genes or proteins. Also provided herein are methods for semen analysis that include (a) measuring a sperm content in a semen sample obtained from a subject; and (b) if the subject has few or no sperm, determining the stages of other germ cells in the semen sample by measuring the expression levels of one or more stage-specific genes or proteins in the germ cell in a semen sample.
[0010] In some embodiments, step (a) comprises measuring ribonucleic acid molecules (RNA) expressed from genes. In some embodiments, the one or more genes comprise one or more stage-specific genes. In some embodiments measuring the level of RNA expression comprises performing polymerase chain reaction (PCR). In some embodiments, PCR comprises quantitative polymerase chain reaction (qPCR), TaqMan probe analysis, reverse transcription PCR (rtPCR), or any combination thereof. In some embodiments the method comprises measuring the protein expression level that mark germ cell stages. In some embodiments, protein detection methods include flow cytometry, ELISA, or a combination thereof.
[0011] In some embodiments, the semen sample is collected from a human male subject. In some embodiments, the method further comprises diagnosing the human male subject with a condition. In some embodiments, the condition comprises infertility or a sub-set thereof (e g., fertility after vasectomy reversal, suppression of fertility due to male contraceptive use, spermatogenesis status prior to chemotherapy, infertility, or a spermatogenic defect). In some embodiments, infertility comprises azoospermia, oligospermia, asthenozoospermia, or teratozoospermia, or any combination thereof. In some embodiments, the method further comprises estimating or predicting the presence or absence of immature germ cells or sperm in the testis of the human male subject based on the semen analysis.
[0012] In some embodiments, the method further comprises recommending or performing an action based on the semen analysis.
[0013] In some embodiments, the action comprises testicular sperm extraction (TESE), followed by in vitro fertilization (IVF) using a procedure called intracytoplasmic sperm injection (ICSI) that involves injecting the extracted sperm into an egg of a female partner of the subject. In some embodiments, the specific method of sperm extraction involves microscopy to identify the sperm in testes; this is called microdissection testicular sperm extraction (mTESE).
[0014] In some embodiments, the condition comprises infertility and presence of elongated spermatids in the testis, and the action comprises extracting one or more elongated spermatids from the testis of the subject, thereby generating extracted elongated spermatids. In some embodiments, the action further comprises injecting the extracted elongated spermatids into an egg of a female partner of the subject, a procedure called intra-cytoplasmic elongated spermatid injection (ELSI).
[0015] In some embodiments, the condition comprises infertility and presence of round spermatids in the testis, and the action comprises extracting one or more round spermatids from the testis of the subject, thereby generating extracted round spermatids. In some embodiments, the action further comprises injecting the extracted round spermatids into an egg of a female partner of the subject, a procedure called round spermatid injection (ROSI).
[0016] In some embodiments, the method further comprises preserving the extracted sperm. In some embodiments, the condition comprises infertility and presence of elongated spermatids in the testis, and the action comprises extracting one or more elongated spermatids from the testis of the subject. In some embodiments, the method further comprises preserving the extracted elongated spermatids. In some embodiments, the condition further comprises infertility and presence of round spermatids in the testis, and the action comprises extracting one or more round spermatids from the testis of the subject. In some embodiments, the condition further comprises preserving the extracted round spermatids. In some embodiments, preserving comprises freezing.
[0017] In some embodiments, one or more cells detected by the test comprise sperm. In some embodiments, one or more immature germ cells detected by the test comprise elongated spermatids. In some embodiments, the one or more immature germ cells detected by the test comprise round spermatids. In some embodiments, the one or more immature germ cells detected by the test comprise spermatocytes. In some embodiments, the one or more immature germ cells detected by the test comprise spermatogonia.
[0018] In some embodiments, the genes whose expression marks cells in the semen are: UCHL1, C19ORF81. PPP1R36, DMRT1, DNMT1, DAZ, DAZL, ID4, KIT, CTCFL, PNMA5, UTF1, GFRA1. PLPPR3, PIWIL4. FSD1, DMC1, SPOIL OVOS2, TEX12, SYCP1, SDF2L1, DMRTBL MAGEA4, LIN7B, HMGA1, ZNF428, LM04, RGMA. ACRC. KLHL15, CCND1. MAGEB2, TCF3, CTSL, TM2D1, PABPC4, ZPBP2, ZPBP, SPAG6, SPEM1, SPEM2, TSSK3, TSSK6, DNAH5, DNAH7, SIRT1, PIWIL3, CHD5, C17ORF98, LRRC3B, IAPP, HDAC11, HBB, FSCN3, CAMK4, PRM1, PRM2, TNP1, TNP2, AURKA, GJA8, MUC12, MROH9, LRRC74B, THAP10. PLCHI, TPRG1. OXCT2, DDX4, CCT2, MAP7D2, RMB46, SMC3, STMN1. TUBA3C , CCDC34, DCDC2C, CDHR2, FAM187B, SPPL2C, KRT15, TEX37, FAM71B, VIM, SOX9, VWF, LCN3 & CD45, GAPDH, HRPT1, PGK1, PPIA, RPL13A, RPS29, TBP, RPL19, or any combination thereof.
[0019] In some embodiments, the genes whose expression marks spermatogonia comprise UCHL1, C19ORF81, PPP1R36, DMRT1, DMRTB1, DAZ, DAZL, ID4, KIT. CTCFL, PNMA5, UTF1, GFRA1, PLPPR3, PIWIL4, FSD1, MAGEA4, LIN7B, HMGA1, SDF2L1, TM2D1, ZNF428, LMO4, RGMA, ACRC, KLHL15, CCND1, MAGEB2, and TCF3.
[0020] In some embodiments, the genes whose expression marks spermatocytes comprise DMC1, DNMT1, SPOIL CTSL, TM2D1, OVOS2, TEX12, SYCP1, SDF2L1, PABPC4, ZPBP, ZPBP2, and SPAG6.
[0021] In some embodiments, the genes whose expression marks spermatids comprise ZPBP2, ZPBP, SPAG6, SPEM1, SPEM2, TSSK3, TSSK6, DNAH5, DNAH7, SIRT1, PIWIL3. CHD5, C17ORF98, LRRC3B, IAPP, HDAC11, HBB, FSCN3. CAMK4, PRML PRM2. TNP1, TNP2, AURKA, GJA8, NUTM1, MUC12, MROH9, LRRC74B, THAP10, PLCH1, TPRG1, and OXCT2.
[0022] In an aspect, provided herein is a non-invasive method for determining whether a male human subject is likely to benefit from testicular sperm extraction procedure, round spermatid injection, elongated spermatid injection for conception or fertilization, wherein the method comprises the method of any one of the preceding embodiments.
[0023] In some embodiments, the method further comprises non-invasive detection of fertility' defects, detection of spermatogenic changes in response to extrinsic treatments, or both.
[0024] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Although methods and materials similar or equivalent to those described herein can be used to practice the invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.
[0025] The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
[0026] BRIEF DESCRIPTION OF DRAWINGS
[0027] The novel features of this disclosure are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the disclosure are utilized, and the accompanying drawings of which:
[0028] FIG. 1 shows an exemplary schematic of a non-invasive diagnostic assay that leverages the fact that a small proportion of immature germ cells are shed from seminiferous tubules in the testis. Left, all stages of immature male germ cells are attached to Sertoli cells in the seminiferous epithelium. Once sperm are formed (cells with the tails in the schematic), they detach from Sertoli cells and travel to the epididymis to become part of semen. Critical for the non-invasive methods described herein, a small proportion of immature germ cells detach from Sertoli cells prematurely, such that they also end up in semen. These prematurely -detached germ cells in semen provide “a window’' into the state of spermatogenesis in the testis. Right, an infertile man with a spermatogenic block at the meiotic stage. Because of this block, this man lacks sperm and only has the immature germ cell stages — called “spermatogonia’' and “spermatocytes” — that precede this spermatogenic block. These early germ cells stages collect in semen and therefore provide a non-invasive indicator of the spermatogenic defect in this infertile subject.
[0029] FIGs. 2A-2B show schematics of an example of the non-invasive diagnostic assay described herein called the molecular semen analysis (MSA) assay and the infertile phenot pes it detects. FIG. 2A shows an exemplary’ MSA assay workflow. FIG. 2B shows that by detecting the expression of stage-specific germ cell markers, the MSA assay can distinguish between the indicated spermatogenic defects. The darker shade rectangle represents strong expression of germ cell stage specific markers while the lighter shade rectangle represents weaker expression.
[0030] FIG. 3 shows the expression pattern of some of the germ-cell gene markers that are used in the MSA assay. The violin plots show the levels of mRNAs encoding by the indicated genes in cell clusters corresponding to the indicated germ cell stages, as defined by singlecell RNA-sequencing (scRNAseq) analysis of adult human testicular cells. SSC, spermatogonial stem cell; Diffing SG, differentiating spermatogonia; SPC, spermatocyte; St, spermatid; Elong, Elongated. All the genes shown are stage-specific in their expression except DDX4 and CCT2 which were selected as pan germ-cell markers because they are expressed in all stages of germ cells.
[0031] FIG. 4 shows that the MSA assay detects SSC and spermatogonia defects in nonobstructive azoospermic (NOA) infertile subjects. Left, cytological analysis of testicular aspirates from several sites from both the left and right testicles (LT & RT, respectively) of 4 male NOA subjects. Shown are the fraction of sites that have detectable early germ cells (eGC), spermatids (ST), sperm (SP), and somatic (non-germ) cells called Sertoli cells (SC). Also shown is the clinical diagnosis: Sertoli cell-only (SCO) syndrome or yveak (hypo) spermatogenesis. Right, a specific application of the present disclosure - qPCR analysis of semen cells from the above subjects. Sho vn is the expression of stage-specific marker genes that mark undifferentiated spermatogonia (uSG; UCHL1), spermatocytes (SPC; ZPBP2), immature spermatids (i-ST; TNP1), mature spermatids (m-ST; SPEM2) and sperm (SP; PRM2). Their expression was normalized to the expression of pan germ-cell markers (DDX4, CCT2, and / or SMC3), also defined by qPCR analysis. All these stage-specific and pan germcell marker genes yvere chosen based on scRNAseq analyses. The mRNA levels shown in the figure are relative to the average mRNA level in semen cells from a cohort of men with normal semen parameters (n = 70; based on WHO guidelines), which was given a value of “1.” ND, not detectably expressed (i.e., Ct value >40). FIGs. 5A-5B show that the MSA assay detects stage-specific spermatogenic defects in non-obstructive azoospermic (NOA) infertile subjects, wherein histological analysis of a testis biopsy from a NOA infertile subject show that some seminiferous tubule cross-sections have a Sertoli cell-only (SCO) syndrome (no germ cells) (FIG. 5A, image A), while other seminiferous tubule cross-sections have spermatogonia (SG; FIG. 5A, image B). Heterogenous tubule phenotypes are commonly observed in azoospermia patients. The sections with SG define this NOA patient as suffering from a SG block (i.e., arrest). Quantification of the germ cell [GC]-to-SC nuclei ratio determined from analyzing 38 cross sections (421 cells) is also shown. FIG. 5A, right panel, shows qPCR analysis, performed as in FIG. 4 on a semen sample from this infertile subject, which confirms the SG-block phenotype. High expression of the differentiated (d) SG marker gene, DMRT1. indicates that this subject’s SG have progressed to the dSG stage and thus this subject specifically suffers from a dSG block. This molecular analysis also indicates expression of later-stage markers, suggesting that the dSG block is not complete and that this subject has some advanced elongated spermatids (and possibly testicular sperm) that could be used for IVF treatment. FIG. 5B. left panel show's histological analysis of testes biopsy from a NOA infertile subject who exhibits meiotic arrest, based on the presence of SG and early-stage (pre-leptotene and leptotene) SPC (both early germ cells) but not later stage (e.g., pachytene) SPC or ST. Quantification of the germ cell [GC]-to-SC nuclei ratio determined from analyzing 18 cross sections (305 cells) is also shown. FIG. 5B. right panel shows qPCR analysis, performed as in FIG. 5A, confirming the meiotic arrest phenotype, based on expression of SG and SPC markers, but not ST markers. See FIG. 4 for definition of all acronyms and other details.
[0032] FIG. 6 shows evidence that two highly sensitive stage-specific germ cell gene markers used by the MSA assay distinguish between early maturation arrest and other spermatogenic defects. mRNA level is plotted on a log scale with a value of 1 representing the average expression in 70 men with normal-range fertility parameters (based on WHO standards). *, p<0.05.
[0033] FIG. 7 shows the MSA assay predicts mTESE success. NOA subjects (N=16) were classified into 3 groups i. pre-meiotic / meiotic block, ii. post-meiotic block and iii. partial defect (the latter includes a partial defect in any stage of spermatogenesis), based on their profile of stage-specific markers, as defined by the MSA assay. The mTESE procedure w as later performed on these subjects and those in which testicular sperm were identified were scored as ‘"successful mTESE.” NOA subjects with a post-meiotic block or a partial progression defect (at any stage) would be predicted to have some testicular sperm or spermatids and thus have a positive mTESE outcome. In contrast, NOA subjects with a pre- meiotic or meiotic block in spermatogenesis would be predicted to produce no or few sperm and thus have a negative mTESE outcome. The results shown match these predictions.
[0034] DETAILED DESCRIPTION
[0035] Infertility is an important condition frequently affecting couples (-15% of the couples in US in year 2023) that leads to various issues, including a reduction in the quality of life, dissatisfaction, and other problems associated with the inability' to conceive a child. In -1% of male infertility' cases, sperm are not detectable in a semen sample of a male subject, based on standard clinical assays. In such azoospermic subjects, sperm are sometimes available in an ‘‘upstream organ” of the male subject - the testis. Among the approaches used to further study, diagnose, and help such azoospermic subjects or male subjects with few sperm is to surgically remove a portion of their testes to determine the presence or absence of sperm therein. In case sperm or a precursor to sperm is available in the testes, such sperm or precursor thereof may be extracted from the testes and used to fertilize an egg of the female partner using a variety of methods such as fine needle aspiration (FNA), testicular sperm extraction (TESE), and microdissection testicular sperm extraction (mTESE). However, using a surgical diagnostic method to assess whether there are sperm or sperm precursors in the testis is invasive. Thus, there is a need for non-invasive and thus more convenient and potentially less harmful method to accomplish this purpose. Such test may further have various other applications which are also provided herein.
[0036] Provided herein is a method of analyzing semen or a sample comprising semen. The profile of germ cells in the semen reflect the profile of germ cells in the testis since a proportion of all the stages of germ cells in the testis leave the testis and go to the epididymis where they become part of semen upon ejaculation. The method may comprise applications for diagnosing fertility or a ty pe thereof. The method may also have various other applications. For example, the method may be used to identify the presence, absence, type, stage of development, or other features of one or more cell types in a semen sample. As described herein, the method can also be used to (i) monitor the acton of fertility7drugs, (ii) diagnose a loss of sperm because of a physical block of their exit from the testis (called obstructive azoospermia), and (iii) monitor the action of male contraceptives designed to temporarily7block fertility. In some embodiments, the method may comprise a genetic test. In some embodiments, the methods of the present disclosure can be used as an indicator or predictive test to determine whether the testis of an infertile subject has sperm.
[0037] Various non-limiting aspects of these methods and compositions are described herein and can be used in any combination without limitation. Additional aspects of various components of the methods and compositions described herein are known in the art.
[0038] It must be noted that, as used in the specification and the appended claims, the singular forms “a,” ‘"an” and "‘the” include plural references unless the context clearly dictates otherwise.
[0039] As used herein, the term “expression” refers to the process by which polynucleotides are transcribed into mRNA and / or the process by which the transcribed mRNA is subsequently translated into peptides, polypeptides, or proteins. In some embodiments, if the polynucleotide is derived from genomic DNA, expression may include splicing of the mRNA in a eukaryotic cell. The expression level of a gene may be determined by measuring the amount of mRNA or protein in a cell or tissue sample; further, the expression level of multiple genes can be determined to establish an expression profile for a particular sample.
[0040] As used herein, the term "subject” refers to an organism, typically a mammal (e.g.. a human). In some embodiments, a subject is suffering from a relevant disease, disorder, or condition. In some embodiments, a subject is susceptible to a disease, disorder, or condition. In some embodiments, a subject displays one or more symptoms or characteristics of a disease, disorder, or condition. In some embodiments, a subject does not display any symptom or characteristic of a disease, disorder, or condition. In some embodiments, a subject is someone with one or more features characteristic of susceptibility to or risk of a disease, disorder, or condition. In some embodiments, a subject is an individual to whom diagnosis and / or therapy is and / or has been administered. In some embodiments, the subject is a human. In some embodiments, the subject is a human male.
[0041] As used herein, the terms “about” and “approximately,” when used to modify an amount specified in a numeric value or range, indicate that the numeric value as well as reasonable deviations from the value known to the skilled person in the art. for example ± 10%. or ± 5%, are within the intended meaning of the recited value.
[0042] Method of Semen Analysis
[0043] Provided herein are methods of semen analysis, the method including (a) measuring a sperm content in a semen sample obtained from a subject; and (b) if the subject has few or no sperm (e.g., is azoospermic). determining the germ cell content in the semen sample, including sperm precursor cells (immature germ cells), by measuring an expression level of one or more germ cell stage-specific genes or proteins.
[0044] In some embodiments, a method described herein can detect spermatogenesis defects from a semen sample, thereby avoiding the expense and difficulty of obtaining a testis biopsy. As used herein, "spermatogenesis" refers to the many steps that immature male germ cells undergo to become sperm (FIG. 1). This includes the proliferation of immature germ cells and their subsequent conversion into haploid cells through the process of meiosis. These haploid cells, referred to as round spermatids, differentiate into elongated spermatids, which subsequently form sperm. Spermatogenesis occurs in a long tube in the testis called the seminiferous tubule. The germ cells undergoing spermatogenesis in this tube are attached to giant somatic nurse cells called Sertoli cells. Soon after sperm are formed, they detach from Sertoli cells and travel down the lumen of the seminiferous tubule to the epididymis, where they are stored until ej aculation, when they become part of semen.
[0045] In some embodiments, a small proportion of all stages of immature germ cells detach from Sertoli cells prematurely and travel down to the epididymis, where they are stored until released as part of semen (FIG. 1). In some embodiments, a method described herein utilizes the specific markers that label these different stages of germ cells in humans. These stagespecific markers were discovered through scRNAseq analysis of the human testis, wherein these genes are sufficiently expressed to be detected in small numbers of semen cells. In some embodiments, by using the stage-specific markers described above, the method detects the precise stage of spermatogenic defect in the testis from a semen sample. In some embodiments, for example, a method described herein can distinguish between Sertoli cell- only (SCO) Syndrome, spermatogonial arrest, spermatocyte arrest, spermatid progression defects, and partial spermatogenic defects (FIG. 2B). In some embodiments, the method can detect a single sperm in a semen sample.
[0046] In standard clinical practice, sperm are detected in semen by a test that involves microscopic observation. If no sperm are detected in semen in its original volume (~0.5 - 1.5 ml) by standard microscopic analysis, sensitivity is increased by centrifuging and resuspending the cell pellet in a smaller volume (e.g., 50 pl). If no sperm are detected after this second procedure, a subject is defined as “azoospermic,” which refers to the subject “having no sperm in the semen.” However, this standard clinical approach can miss small numbers of sperm and thus a subject defined as having azoospermia may have some sperm in their semen. The method herein can detect even a single sperm.
[0047] In some embodiments, azoospermic subjects have precursor sperm (“spermatids”) that, like sperm, are haploid (i.e., having one copy of the genome) and thus are capable of fertilizing an egg. In some embodiments, a spermatid is called an elongated spermatid, which has different tail lengths depending on its stage of maturation, and is the direct precursor of sperm. When injected into human eggs, human elongated spermatids have been shown (in publications) to fertilize eggs, which go on to form embryos in vitro and ultimately make healthy babies. In some embodiments, a spermatid is called a round spermatid, which are the stage that gives rise to elongated spermatids. Round spermatids have no tail and thus can be readily distinguished from earlier stage germ cells. While round spermatids are less mature than elongated spermatids, they are haploid (like elongated spermatids), and have been shown (in publications) to fertilize human eggs which go on to form embryos in vitro and ultimately make healthy babies.
[0048] In some embodiments, the methods described herein can detect both spermatids (e.g., round spermatid and elongated spermatid) and sperm. Furthermore, in some embodiments, the methods described herein are extremely sensitive and are able to detect even a single spermatid or sperm. This sensitivity7stems from methods described herein that use PCR to detect specific RNA marker molecules that are typically present in several copies in a single cell.
[0049] In some embodiments, provided herein is a method of semen analysis that includes (a) measuring a level of an expression of one or more genes or proteins in a semen sample; and (b) predicting or determining a presence, an absence, a type, or a stage of one or more of sperm, immature germ cells, or cell types in the semen, based on the expression of the one or more genes or proteins in the semen sample. In some cases, the method is capable of detecting a low concentration of sperm in a semen sample, such as less than 100 sperm / detection limit. In some embodiments, the semen sample contains few sperm, no sperm, few immature germ cells (e.g., round spermatids, elongated spermatids), no immature germ cells, or any combinations thereof. In some embodiments, the semen sample is collected from a human male subject.
[0050] In some embodiments, a method described herein further comprises estimating or predicting the presence or absence of immature germ cells or sperm in a testis of the human male subject, non-invasively, based on the semen analysis. In some embodiments, the one or more immature germ cells comprise elongated spermatids. In some embodiments, the one or more immature germ cells comprise round spermatids. In some embodiments, the one or more immature germ cells comprise spermatocytes. In some embodiments, the one or more immature germ cells comprise spermatogonia.
[0051] In some embodiments, the method described herein (a) comprises measuring RNA expression. In some embodiments measuring the level of RNA expression comprises performing PCR. In some embodiments, the one or more genes comprise one or more cell stage-specific genes. In some embodiments. PCR comprises quantitative polymerase chain reaction (qPCR), TaqMan probe analysis, reverse transcription PCR (rtPCR), or any combination thereof. In some embodiments the method comprises measuring the levels of proteins that mark germ cell stages. Such protein detection methods include, but are not limited to, flow cytometry. ELISA, or a combination thereof.
[0052] Method used to diagnose a condition based on semen analysis
[0053] In some embodiments, a method described herein further comprises diagnosing or monitoring the subject (e.g., human male subject) with a condition. In some embodiments, the condition comprises infertility, sub-fertility, or a subset thereof. In some embodiments, infertility comprises azoospermia, oligospermia, asthenozoospermia, or teratozoospermia, or any combination thereof. In some embodiments, spermatogenic defects comprise azoospermia, oligospermia, asthenozoospermia, teratozoospermia, or any combinations thereof. In some cases, the condition comprises infertility and presence of sperm in the testis, and the action comprises extracting one or more sperm from the testis of the subject, thereby generating extracted sperm. In some embodiments, the methods described herein can indicate that a given infertility subject has a tubal block defect, wherein the tubal block prevents the sperm generated in the testis from becoming a component of semen, a condition called obstructive azoospermia.
[0054] In some embodiments, the method described herein is used to determine the effect of fertility treatments on infertile individuals. In some embodiments, a fertility treatment can comprise treatment with gonadotropins (e.g., follicle-stimulating hormone [FSH] or luteinizing hormone [LH]) or natural or synthetic versions of gonadotropins. In some embodiments, a fertility treatment can comprise treatments that influence the release of follicle-stimulating hormone (FSH) or luteinizing hormone (LH) from the pituitary; such as treatment with forms of gonadotropin-releasing hormone (GnRH), which is normally produced by the hypothalamus. In some embodiments, a fertility treatment can comprise treatments with forms of retinoic acid (RA), such as 13-cis RA (isotretinoin), to promote male fertility.
[0055] In some embodiments, the method described herein is used to assess spermatogenesis after vasectomy reversal. In some embodiments, assessment of spermatogenesis after vasectomy reversal will allow one to infer return of fertility.
[0056] In some embodiments, a method described herein comprises diagnosing or monitoring a likely fertile human male subject that is undergoing a procedure that may affect the subject’s fertility. In some embodiments, the method is used to determine effectiveness of a male contraceptive on a fertile male subject. In some embodiments, the method described herein is used to monitor the effect of a male contraceptive on spermatogenesis over time. In some embodiments, the method is to determine spermatogenesis status prior to chemotherapy. In some embodiments, the method is used to determine if it is appropriate to bank sperm prior to chemotherapy.
[0057] Method used to recommend or perform an action based on semen analysis
[0058] In some embodiments, a method described herein further comprises recommending or performing an action based on semen analysis. In some embodiments, the action comprises testicular sperm extraction (TESE), microdissection testicular sperm extraction (mTESE), and in vitro fertilization (IVF). Examples of IVF can include intracytoplasmic sperm injection (ICSI), elongated spermatid injection (ELSI), round spermatid injection (ROSI).
[0059] As used herein, "testicular sperm extraction (TESE)” refers to a procedure to collect sperm directly from the testes of a subject, and "microdissection testicular sperm extraction (mTESE)” refers to a procedure to collect sperm directly from the testes of a subject, wherein the mTESE relies on an operating microscope and microsurgical technique to identify and extract seminiferous tubules more likely to contain sperm.
[0060] In some embodiments, if the method indicates that the infertile subject is predicted to have sperm in the testis, this will indicate to the physician that testicular sperm extraction (TESE) or microdissection testicular sperm extraction (mTESE) is justified. In some embodiments, the action further comprises injecting the extracted sperm into an egg by performing a procedure called intra-cytoplasmic sperm injection (ICSI), which is a form of in-vitro fertilization (IVF). As used herein, ‘TCSI” refers to a process that includes injecting the extracted sperm into an egg. In some embodiments, the extracted sperm will be used for another form of IVF in which the extracted sperm is co-incubated with the egg. In some embodiments, if the subj ect is predicted to have elongated spermatids in the testis and is diagnosed with infertility, the method includes determining the probability of extracting one or more elongated spermatids from the testis of the subject, thereby generating extracted elongated spermatids. In some embodiments, the action further comprises injecting the extracted elongated spermatids into an egg by a procedure called elongated spermatid injection (ELSI). As used herein, “ELSI” refers to a process that involves injecting the extracted round spermatids into an egg of a female partner of the subject.
[0061] In some embodiments, if the subject is predicted to have round spermatids in the testis and is diagnosed with infertility, the method includes determining the probability of extracting one or more round spermatids from the testis of the subject, thereby generating extracted round spermatids. In some embodiments, the action further comprises injecting the extracted round spermatids into an egg by a procedure called round spermatid injection (ROSI). As used herein, “ROSE’ refers to a process that involves injecting the extracted round spermatids into an egg of a female partner of the subject.
[0062] In some embodiments, a method described herein can be used to analyze extracted sperm or spermatids after they have been frozen in liquid nitrogen by a process called “cry opreservation.” When thawed, such sperm or spermatids can be used for IVF. In some embodiments, a method described herein can be used to compare extracted sperm or spermatids that have been cryopreserved vs. not frozen.
[0063] Measuring expression level of one or more cell stage-specific genes
[0064] In some embodiments, a method described herein includes analyzing a germ cell in a semen sample by measuring an expression level of one or more stage-specific genes or proteins in the germ cell.
[0065] In some embodiments, the one or more genes are selected from: UCHL1, C19ORF81, PPP1R36, DMRT1, DNMT1, DAZ, DAZL. ID4, KIT, CTCFL, PNMA5, UTF1, GFRA1. PLPPR3, PIWIL4, FSD1, DMC1. SPOIL OVOS2, TEX12, SYCP1, SDF2L1, DMRTB1. MAGEA4, LIN7B, HMGA1, ZNF428, LMO4, RGMA, ACRC, KLHL15, CCND1, MAGEB2, TCF3, CTRL, TM2D1, PABPC4, ZPBP2, ZPBP, SPAG6, SPEM1, SPEM2, TSSK3, TSSK6, DNAH5, DNAH7, SIRT1, PIWIL3, CHD5, C17ORF98, LRRC3B, IAPP, HDAC11, HBB, FSCN3, CAMK4. PRM1. PRM2, TNP1, TNP2, AURKA. GJA8, MUC12, MROH9, LRRC74B, THAP10, PLCHI, TPRG1, OXCT2, DDX4, CCT2, MAP7D2, RMB46, SMC 3, STMN1, TUBA3C , CCDC34, DCDC2C, CDHR2, FAM187B, SPPL2C, KRT15, TEX37, FAM71B, VIM, SOX9, VWFLCN3, CD45, GAPDH, HRPT1, PGK1, PPIA, RPL13A, RPS29, TBP, RPL19, or any combination thereof.
[0066] In some embodiments, expression of one or more genes from UCHL1, C19ORF81, PPP1R36, DMRT1, DMRTB1, DNMT1, DAZ, DAZL, ID4, KIT, CTCFL, PNMA5, SDF2L1, TM2D1, UTF1, GFRA1, PLPPR3, PIWIL4, FSD1, MAGEA4, LIN7B, HMGA1, ZNF428, IMO4, RGMA, ACRC, KLHL15, CCND1, MAGEB2. or TCF3 indicates spermatogonia.
[0067] In some embodiments, expression of one or more genes from PNMA5. DMC1, DNMT1, SPO11, CTSL, TM2D1, OVOS2, TEX12, SYCP1, SDF2L1, PABPC4, ZPBP, ZPBP2, or SPAG6 indicates spermatocytes.
[0068] In some embodiments, expression of one or more genes from ZPBP2, ZPBP, SPAG6, SPEM1, SPEM2. TSSK3. TSSK6, DNAH5, DNAH7, SIRT1, PIWIL3, CHD5, C17ORF98, LRRC3B, LAPP, HDAC11, HBB, FSCN3. CAMK4, PRM1, PRM2, TNP1, TNP2, AURKA, GJA8, MUC12, MROH9, LRRC74B, THAP10, PLCHI, TPRG1, or OXCT2 indicates spermatids.
[0069] In some embodiments, expression of one or more genes from DCDC2C, CDHR2. FAM187B, SPPL2C, KRT15, TEX 37. or FAM7 IB indicates sperm.
[0070] In some embodiments, the one or more genes are selectively expressed in the germ cell ty pe.
[0071] In some embodiments, the one or more genes whose expression indicates somatic cells in the testis comprise: VIM (somatic cells). SOX9 (Sertoli cells). VWF (endothelial cells), LCN3 & CD45 (leukocytes).
[0072] In some embodiments, the one or more genes whose expression indicates all germ cells in the testis (i.e., not stage-specific) comprise: DDX4, CCT2, MAP7D2, RMB46, SMC3, STMN1, or TUBA3C. In some embodiments, the one or more genes whose expression indicates all germ cells in the testis ('‘pan” germ-cell marker genes) are used to quantify the proportion of semen cells that are germ cells.
[0073] In some embodiments, the one or more genes that are expressed in all cells in the testis (including both germ cells and somatic cells) include GAPDH. HRPT1, PGK1, PPIA, RPL13A, RPL19, RPS29, or TBP.
[0074] Therapeutic Applications
[0075] Also, provided herein are non-invasive methods for determining whether a male human subject is likely to benefit from a testicular sperm, elongated spermatid, or round spermatid extraction procedure, followed by injection of the testicular sperm, elongated spermatids, or round spermatids into an egg, wherein the method comprises the method of any one of the preceding embodiments. In some embodiments, the method further comprises non-invasive detection of fertility defects, detection of spermatogenic changes in response to extrinsic treatments (e.g., fertility treatments, spermatogonial stem cell (SSC) therapy), or both.
[0076] Identification of infertility subjects eligible for in vitro fertilization (IVF) with semen-derived germ cells
[0077] In some embodiments, the methods described herein can identify infertility subjects eligible for IVF with semen-derived haploid germ cells. Round spermatids are haploid precursors to more advanced precursor haploid germ cells called elongated spermatids, which are themselves direct precursor to sperm. Like testicular sperm, round and elongated spermatids can be injected into oocytes (i.e., by a procedure analogous to ICSI) to improve fertility. Most round and elongated spermatids are attached to Sertoli cells in the testis as they undergo maturation into sperm, but a small proportion of them detach prematurely and therefore travel to the epididymis, where they can be ejaculated as part of semen. In some embodiments, the semen analysis methods of the present disclosure can detect the presence of these round or elongated spermatids in semen. In some embodiments, if the semen analysis methods of the present disclosure detect spermatids in an infertility subject, such as an azoospermic subject, these could be used to fertilize an egg.
[0078] In some embodiments, the methods suggest that some infertility’ subjects have sufficient numbers of spermatids or sperm in semen for physicians to consider using these semen-derived germ cells directly for IVF, wherein this alternative approach would avoid the challenges of testicular surgery’ to retrieve elongated spermatids from the testis. In some embodiments, another advantage of the methods described herein is that they can provide a rich source of spermatids or sperm even if there is only focal spermatogenesis (i.e., spermatogenesis occurring in only isolated regions of the testis) which could be missed in a testicular biopsy.
[0079] Identification of subjects most likely to benefit from round spermatid injection (ROSI)
[0080] In some embodiments, the methods described herein can identify subjects most likely to benefit from ROSI. Like elongated spermatids, round spermatids are haploid cells that have already undergone meiosis and thus are capable of fertilizing haploid oocytes to generate diploid embryos. Studies conducted in both humans and mice have shown that ROSI into oocytes can yield live progeny. However, for an infertility subject to benefit from ROSI, the subject must have germ cells that have progressed to the round spermatid stage of development. In some embodiments, the methods of the present disclosure can detect whether an infertility subject has germ cells that have progressed to the round spermatid stage of development, and thus whether the subject can benefit from ROSI. In some embodiments, the methods described herein can demonstrate the identification of cells in semen from several infertility7subj ects (including those wi th either azoospermia or oligospermia) that highly express round spermatid markers (e.g., AURKA and GJA8) (FIG. 3).
[0081] In some embodiments, the methods of the present disclosure allow physicians to determine whether round spermatids are present in the testis of an infertility subject without requiring an invasive testicular biopsy. In some embodiments, an additional advantage of the method of the present disclosure is that it has the potential to distinguish between subjects with immature vs. advanced round spermatids. Subjects with advanced round spermatids may be more likely to successfully fertilize oocytes.
[0082] Other scenarios in which non-invasive methods could prove useful
[0083] In some embodiments, the methods described herein can indicate that a given infertility' subject has any tubal block defect, wherein the tubal block prevents the sperm generated in the testis from becoming a component of semen. Standard semen analysis is not able to identify these “obstructive azoospermia” subjects and there is currently no direct method to identify this condition except for an abdominal scan. In some embodiments, the semen analysis methods of the present disclosure can reliably infer an obstruction defect and thus diagnose subjects with obstructive azoospermia.
[0084] In some embodiments, the method of the present disclosure can indicate that a given infertility subject has neither spermatids nor sperm in the testis. For example, a common infertility7condition is called “meiotic arrest,” in which the male germ cells arrest at the spermatocy te (meiotic) stage. Unfortunately, there is currently no fertility' treatment for this condition. In some embodiments, the methods described herein can indicate this condition without obtaining an invasive testicular biopsy. Thus, the test of the present disclosure prevents unnecessary' surgeries. Another common infertility- condition is called “Sertoli cell-only syndrome (SCO).” In such cases, histological analysis fails to show any germ cells in seminiferous tubules. However, in reality, SCO subjects often have some germ cells, typically the least advanced germ cells called spermatogonia. In some embodiments, the methods provided herein can distinguish between such cases of spermatogonial arrest and “true” SCO syndrome in which there are only Sertoli cells, no germ cells. These stem cells are essential for the ongoing spermatogenic process that operates in males from puberty to old age. In some embodiments, a method described herein can detect SSC and spermatogonia defects in non-obstructive azoospermic (NOA) subjects. SSC therapy is an active subject of current research. By detecting the presence of SSCs, the method described herein can determine whether an individual can benefit from such therapy.
[0085] Detection of spermatogenic changes in response to extrinsic treatments
[0086] In some embodiments, the methods described herein detect spermatogenic changes in response to extrinsic treatments. Fertility is not only influenced by intrinsic (e.g., genetic) determinants. Extrinsic events, such as hormone treatment and chemotherapy, can positively or negatively affect fertility, respectively. Currently, the only realistic “readout” of the effect of such extrinsic events is standard semen analysis, which only assays the end-product of spermatogenesis: sperm.
[0087] In some embodiments, the methods of the present disclosure provide an opportunity to also assay earlier events in spermatogenesis. For example, in some embodiments, for subjects undergoing hormone (e.g., gonadotropin) therapy or retinoic acid (e.g., isotretinoin) therapy to upregulate spermatogenesis, the method of the present disclosure can monitor the increase in specific germ cell types as spermatogenesis is improved over time. In some embodiments, for infertility caused by androgen treatment (e.g., for body builders), the methods of the present disclosure can track the improvements to spermatogenesis after androgen is withdrawn. In some embodiments, the methods of the present disclosure can also determine, without testes biopsy, the extent of damage to spermatogenesis caused by chemotherapy treatment. In some embodiments, the methods of the present disclosure can track the effects of other medications, as well as surgeries and environmental exposure to genotoxic substances. In some embodiments, the methods of the present disclosure can track the effects of the complex interplay of different environmental agents and genoty pes on spermatogenesis. Determination of effectiveness, specificity, timing, and reversibility of male contraceptives
[0088] Vasectomy reversal
[0089] Currently, the only available long-term contraceptive for use in males is vasectomy. It is not uncommon for men to seek a reversal of this procedure (e.g., due to a change in family situation). Vasectomy reversal involves a major operation and is often either not successful or only partially successful. In some embodiments, a method of the present disclosure can determine spermatogenesis status after the vasectomy reversal operation. In some embodiments, based on such results, treatment methods can be used to treat possible postvasectomy reversal defects such as (i) blocks in specific spermatogenesis stages, (ii) autoimmune responses against the sperm or (iii) other forms of inflammation.
[0090] Male contraceptive clinical trials
[0091] Clinical trials are currently underway to test several potential alternative male contraceptives. The success of these male contraceptives is currently determined by sperm count and pregnancy outcome. In some embodiments, a method of the present disclosure can provide critical information (e g., for FDA approval) not conferred by sperm count. For example, in some embodiments, the method can provide: (i) a rapid measure of whether the contraceptive is working or not (e.g., results in days / weeks, not months), (ii) rapid determination of the efficiency of the blockade on spermatogenesis, (iii) rapid determination of the step(s) of spermatogenesis impacted by the male contraceptive and / or (iv) rapid determination of reversibility. In some embodiments, these cannot be assessed unless a testes biopsy is performed, wherein not only is obtaining a testes biopsy invasive and expensive, but it is also not feasible to perform on a regular basis. In some embodiments, a method described herein can be used on a regular (e.g., monthly, weekly, or even daily) basis to determine the impact of a male contraceptive.
[0092] Male contraceptive clinical trials in monkeys
[0093] In some embodiments, a method of the present disclosure can be used to assess the efficacy of new male contraceptives in monkey models, a topical step in drug development before clinical trials in humans. In some embodiments, a method described herein can be used to detect monkey genes, as it is known that many stage-specific human spermatogenesis marker genes have a conserved expression pattern in monkey species. Assessment of novel contraceptives in individual users once FDA approval is established
[0094] In some embodiments, once new male contraceptives are approved for use in the future, a method described herein can be used to rapidly assess the contraceptive’s effectiveness in individual users. This may be critical given individual human variation, including variation associated with race and ethnicity.
[0095] Assessment of pre-chemotherapy spermatogenesis status
[0096] It is well established that chemotherapy can render men infertile, with some men being more susceptible to chemotherapy than others. In some embodiments, a method of the present disclosure can assess whether spermatogenesis is normal in the subject prior to chemotherapy. In some embodiments, this information may be helpful in determining whether the subject might benefit from cry opreserving sperm and / or other fertility preservation treatments prior to chemotherapy treatment.
[0097] In some embodiments, a method described herein can distinguish different kinds of spermatogenesis defects in patients prior to chemotherapy. These spermatogenesis defects may lead to decreased sperm count or complete absence of sperm (azoospermia). In some embodiments, a method described herein can also identify obstructive azoospermia in such subjects. In some embodiments, a method described herein can give predictive information for potential mTESE success in such subjects. In some embodiments, a method described herein can categorize such subjects as to whether they have pre-meiotic or post-meiotic defects in spermatogenesis, whether the defect / block is partial or complete, which can be used to determine the probability of success of fertility treatments.
[0098] EXAMPLES
[0099] The disclosure is further described in the following examples, which do not limit the scope of the disclosure.
[0100] Basic method
[0101] A semen sample is centrifuged to pellet the cells present in the semen, washed in IX PBS, pelleted again, and then the RNA from the cell pellet is extracted (FIGs. 2A & 2B, left) The RNA is reverse transcribed to generate cDNA, which is used for qPCR analysis with a custom panel of stage-specific marker genes, as described below (FIGs. 2A & 2B, left). The expression value of stage-specific marker genes is normalized to the expression of pan-germ cell marker genes that are expressed in all germ cells. This allows for the determination of the proportion of different germ cell stages in the semen.
[0102] Example outcomes
[0103] Interpretation of qPCR data from the non-invasive test is as follows. If there is a complete block at a given stage of spermatogenesis, this predicts that the marker expression signal for that germ cell stage, as well as earlier stages, will be stronger than for later stages (FIG. 2B, right). For example, if the subject has meiotic arrest (a common condition), there will be a signal for spermatogonia and spermatocyte markers, but little or no signal for spermatid markers. Alternatively, if the subject has a later stage defect where the subject makes some testicular sperm, the semen cells will also have a signal for spermatid markers. Such a subject will be a candidate for TESE / IVF treatment, as described below.
[0104] How the test was developed
[0105] Cells were purified from semen from azoospermic men, who, by definition, have no sperm in their semen. The few cells they may have in their semen are immature germ cells (the basis of the assay provided herein, in some embodiments) and / or non-germ cells, such as leukocytes. For comparison, semen cells were purified from men with normal sperm parameters. Next, RNA was purified from semen cells from these different types of individuals, followed by qPCR analysis with the highly expressed housekeeping gene RPL19. This qPCR analysis yielded a detectable signal, showing that the method was viable (FIG. 2A).
[0106] A list of stage-specific human germ cell genes was then generated from scRNAseq datasets (FIG. 3). Genes expressed selectively in a given germ-cell stage were selected. Genes were chosen not only because of their stage specificity but, w hen the information was available, for their high expression, as this made it more likely that their expression could be detected by qPCR from small numbers of semen cells.
[0107] These stage-specific genes were then screened for detectable expression in the above semen samples. This analysis defined several germ-cell genes that are detectably expressed in semen cells. This analysis also provided evidence that all stages of germ cells are present in the semen of at least some infertile subjects. To determine whether the qPCR assay of the present disclosure is specific, postvasectomy subjects were tested. Vasectomy involves cutting the vas deferens, so no germ cells from the testes or epididymis can become part of semen. Only germ-cell gene markers expressed at background levels in semen cells from these post-vasectomy subjects were selected to be used for the MSA assay.
[0108] Next, genes were identified that allow one to calculate the proportion of all germ cells that are in a given stage. These “pan7’ germ-cell marker genes are expressed at similar levels at all stages of male germ cell development. Candidate pan germ-cell marker genes were identified from scRNAseq datasets. These pan-germ cell markers are critical for determining the proportion / number of germ cells in semen by serving as the “denominator’’ for calculating the proportion of different germ cell stages that are present in a given semen sample.
[0109] The expression profile of a panel of 14 germ-cell genes and 3 pan germ cell genes were analyzed in 40, 19 and 70 human males having azoospermia, oligospermia, and normal sperm parameters (based on WHO guidelines), respectively. The methods may further comprise using the tests of the present disclosure to validate semen-histology correlation in subjects undergoing surgical sperm extraction.
[0110] In some embodiments, a candidate marker gene (identified from scRNAseq datasets, as described above) that was tested by qPCR for detectable expression in human testes biopsies and semen cells can include, but is not limited to, UCHL1, C19ORF81, PPP1R36, DMRT1, DMRTB1, DAZ, DAZL. ID4, KIT, CTCFL. UTF1, GFRA1, PLPPR3, PIWIL4, FSD1, MAGEA4, LIN7B. HMGA 1. ZNF428. LMO4, RGMA, ACRC, KLHL15, CCND1. MAGEB2, TCF3, SDF2L1, TM2D1, PNMA5, CTCFL, KIT, DMC1, DNMT1, SPO11, CTSL, OVOS2, TEX12, SYCPI, PABPC4, ZPBP, SPAG6, ZPBP2, SPEM1, DNAH5. DNAH7, SIRT1, PIWIL3, CHD5, C17ORF98, LRRC3B, IAPP, HDAC11. HBB, TNPI, TNP2, FSCN3. CAMK4, AURKA, GJA8, MUC12, MR0H9, LRRC74B, THAP10, UTML TMEM243, SPEM2, TSSK3, TSSK6, PRM1, PRM2, PLCH1, TPRG1, OXCT2, DCDC2C, CDHR2, FAM187B, SPPL2C, KRT15, TEX37, FAM71B, DDX4, CCT2, MAP7D2, RMB46, SMC3, STMN1, TUBA3C, or CCDC34. In some embodiments, a candidate marker gene that was tested by qPCR for detectable expression in spermatogonia can include, but is not limited to. UCHL1, C19ORF81, PPP1R36, DMRT1, DMRTB1, DNMT1, DAZ, DAZL, ID4, KIT, CTCFL, PNMA5, SDF2L1, TM2D1, UTF1, GFRA1, PLPPR3, PIWIL4, FSD1, MAGEA4, LIN7B, HMGA1, ZNF428, IMO4, RGMA, ACRC, KLHL15. CCND1, MAGEB2, or TCF3. In some embodiments, a candidate marker gene that was tested by qPCR for detectable expression in spermatocytes can include, but is not limited to, PNMA5, DMC1, DNMT1, SPOIL CTSL, TM2D1, OVOS2, TEX12, SYCP1, SDF2L1, PABPC4, ZPBP, ZPBP2 or SPAG6. In some embodiments, a candidate marker gene that was tested by qPCR for detectable expression in spermatids can include, but is not limited to, ZPBP2, ZPBP, SPAG6. SPEM1, SPEM2, TSSK3, TSSK6, DNAH5, DNAH7, SIRT1, PIWIL3, CHD5, C17ORF98, LRRC3B, IAPP, HDAC11, HBB, FSCN3, CAMK4, PRM1, PRM2, TNP1, TNP2, AURKA, GJA8, MUC12, MROH9, LRRC74B, THAP 10, PLCHI, TPRG1, NUTM1, TMEM243. or OXCT2. In some embodiments, a candidate marker gene that was tested by qPCR for detectable expression in sperm can include, but is not limited to, DCDC2C, CDHR2, FAM187B, SPPL2C, KRT15, TEX 37. or FAM71B. In some embodiments, a candidate marker gene that is a pan-germ cell marker gene (i.e., expressed relatively equally by all stages) can include, but is not limited to, DDX4, CCT2, MAP7D2, RMB46, SMC3, STMNL CCDC34 or TUBA3C. In some embodiments, a candidate marker gene that is expressed by non-germ cell types in the testis can include, but is not limited to, VIM (somatic cells), SOX9 (Sertoli cells), VWF (endothelial cells), LCN3 & CD45 (leukocytes). In some embodiments, a candidate marker gene that is a housekeeping gene (i.e., expressed by all cell types) can include, but is not limited to, RPL19.
[0111] In some embodiments, a candidate marker gene is detectably expressed by qPCR (Ct <32) in a testis biopsy from a normal subject and / or are detectably expressed in most semen samples from men with normal sperm parameters (Ct <37), wherein the candidate marker gene is expressed in spermatogonia, and the candidate marker gene includes UCHL1, C19ORF81, PPP1R36. DMRTL DMRTB1, DAZ, DAZL, ID4, KIT, CTCFL, UTFL GFRA1, PLPPR3, PIWIL4, FSD1, MAGEA4, LIN7B, HMGA 1, , ZNF428, LMO4, RGMA, ACRC, KLHL15, CCND1, MAGEB2, PNMA5, CTCFL, MAGEA4, KIT or TCF3. In some embodiments, the candidate marker gene is expressed in spermatocytes and the candidate marker gene includes PNMA5. DMCL DNMTL SPOIL CTSL, TM2D1, OVOS2. TEX12, SYCP1, SDF2L1, PABPC4, ZPBP, ZPBP2. or SPAG6. In some embodiments, the candidate marker gene is expressed in spermatids and the candidate marker gene includes ZPBP2, ZPBP, SPAG6, SPEM1, SPEM2, TSSK3, TSSK6, DNAH5, DNAH7, SIRT1, PIWIL3, CHD5, C17ORF98, LRRC3B, LAPP, HDAC11, HBB, FSCN3, CAMK4, PRM1, PRM2, TNP1, TNP2, AURKA, GJA8, MUC12, MROH9, LRRC74B, THAP 10. PLCHI, TPRG1, NUTM1.TMEM243 or OXCT2. In some embodiments, the candidate marker gene is expressed in sperm and the candidate marker gene includes DCDC2C, CDHR2, FAM187B, SPPL2C, KRT15, TEX 37. or FAM71B. In some embodiments, a candidate marker gene that is a pan-germ cell marker gene (i.e., expressed relatively equally by all stages) can include DDX4, CCT2, MAP7D2, RMB46, SMC3, STMNL CCDC34, or TUBA3C. In some embodiments, a candidate marker gene that is expressed by non-germ cell types in the testis can include VIM (somatic cells), SOX9 (Sertoli cells), VWF (endothelial cells), LCN3 & CD45 (leukocytes). In some embodiments, a candidate marker gene that is a housekeeping gene (i.e., expressed by all cell types) can include, but is not limited to, RPL19.
[0112] As a negative control, semen samples from 10 post-vasectomy subjects were examined. None of the germ cell markers above were detectably expressed in these semen samples, with the exception of C19ORF81 and TEX12, which had low expression, perhaps due to weak expression in non-germ cells present in semen.
[0113] Example 1 - The MSA assay detect SSC and spermatogonia defects in non-obstructive azoospermic (NOA) subjects
[0114] To determine the validity of the molecular semen analysis (MSA) assay, the results of this semen assay were compared with spermatogenic defects determined by direct analysis of the testis. Cytological analysis was performed on testicular aspirates from several sites from both the left and right testicles (LT & RT, respectively) of 4 non-obstructive azoospermic (NOA) subjects (FIG. 4. left). The results show the fraction of sites that have detectable early germ cells (eGC), spermatids (ST), sperm (SP), and somatic (non-germ) cells called Sertoli cells (SC). Based on this data, the clinical diagnosis for 2 of the patients was Sertoli cell-only (SCO) syndrome and weak (hypo) spermatogenesis for the other 2 patients.
[0115] The above diagnosis was then compared with the results of the MSA qPCR assay (FIG. 4, right). The results show the expression of stage-specific marker genes that mark undifferentiated spermatogonia (uSG; UCHL1), spermatocytes (SPC; ZPBP2 immature spermatids (i-ST; TNP1), mature spermatids (m-ST; SPEM2) and sperm (SP; PRM2 Their expression was normalized to the expression of pan germ-cell markers (DDX4. CCT2. and / or SMC 3). also defined by qPCR analysis. All these stage-specific and pan germ-cell marker genes were chosen based on scRNAseq analyses. The mRNA levels shown in the results are relative to the average mRNA level in semen cells from a cohort of men with normal semen parameters (n = 70), which was given a value of “1.” ND, not detectably expressed (i.e., Ct value >40) (FIG. 4).
[0116] The expression pattern of these stage-specific markers defined a “molecular diagnosis” for each subject. For subject BAI, the molecular diagnosis matches the “cytological diagnosis” described above. For subject BA2, both the molecular and cytological analyses agree that there are no late-stage germ cells, but the molecular assay, which is far more sensitive than cytological analysis, revealed the presence of immature germ cells — uSG — indicative of a SG block rather than SCO.
[0117] For subjects BA3 and BA4, cytological analysis defined these subjects as having hypo-spermatogenesis, based on the presence of some germ cells (albeit low numbers) at all stages examined: eGC, ST, and SP. The molecular assay provided a molecular explanation for this hypo-spermatogenesis defect - it showed high expression of the uSG marker gene, UCHI.l. and very low expression of later stage marker genes, implying a partial block in SG progression. In summary, the non-invasive molecular semen assay provides a diagnosis that both confirms and extends the diagnosis provided by a standard clinical (invasive) assay - cytological analysis of the testes.
[0118] Example 2 - The MSA assay detects stage-specific spermatogenic defects in infertile subjects
[0119] To further test the veracity of the MSA assay, the histological and molecular phenotype of non-obstructive azoospermia (NOA) subject MA58 were analyzed (FIG. 5A). Histological analysis of a testes biopsy from this subject showed that some seminiferous tubule cross-sections have a SCO phenotype (no germ cells) (FIG. 5A, image A), while others have SG (FIG. 5A, image B). Heterogenous tubule phenotypes are commonly observed in azoospermia subjects. The sections with SG demonstrate that this NOA subject suffers from a SG block (i.e., arrest). To determine if the MSA assay is able to detect this SG block, qPCR analysis was performed on a semen sample from this subject. This qPCR confirmed the SG-block phenoty pe. High expression of the differentiated (d) SG marker gene, DMRT1, indicates that this subject’s SG have progressed to the dSG stage and thus this subject specifically suffers from a dSG block in germ cell development. This molecular analysis also indicates expression of later-stage markers, suggesting that the dSG block is not complete and that this subject has some advanced elongated spermatids (and possibly testicular sperm) that could be used for IVF treatment.
[0120] The histological and molecular phenotype of NOA subject MA33 were also analyzed (FIG 5B). Histological analysis of testes biopsy from this subject showed that some seminiferous tubule cross-sections have a SCO phenotype (no germ cells) (FIG. 5B. image A), while other seminiferous tubule cross-sections have early germ cells (eGCs) (FIG. 5B, image B). Heterogenous tubule phenotypes are commonly observed in azoospermia subjects. In the tubules with eGCs, SG and pre-leptotene and leptotene SPC were observed, but not later-stage germ cells, including pachytene SPC and ST, indicating that this NOA subject suffers from a meiotic (SPC) block (i.e., arrest). qPCR analysis performed on a semen sample from this subject confirmed that they suffer from meiotic (SPC) arrest. See FIG. 4 for definition of all acronyms and other details.
[0121] Example 3 - Using the MSA assay to distinguish between early maturation arrest and other spermatogenic defects
[0122] NOA subjects were classified into 3 groups (depicted in FIG. 6) based on germ cell stage-specific marker genes identified from scRNAseq analysis. FIG. 6 shows how these 3 NOA subject groups express two spermatid / sperm marker genes that were chosen because of their high expression, allowing high sensitivity.
[0123] Post-meiotic defect subjects.
[0124] This group exhibited relatively high average expression of the 2 spermatid / sperm marker genes. However, the average expression was between -100- and -1000-fold lower than in semen from individuals with normal fertility parameters (based on the WHO; note the data in FIG. 6 is depicted on a log scale), consistent with these being NOA subjects who, by definition, have few or no sperm, and may or may not have spermatids. This group would be predicted to have a high chance of mTESE success.
[0125] Pre-meiotic / meiotic block subjects.
[0126] This group exhibited the lowest average expression of the 2 spermatid / sperm marker genes (-1,000 fold lower than the post-meiotic defect subjects), which is consistent with these patients having an early block in spermatogenesis, largely preventing them from generating spermatids or sperm. This group would be predicted to have an extremely low chance of mTESE success.
[0127] Partial block subjects.
[0128] This group exhibited high average expression of the 2 spermatid / sperm marker genes, very similar to that of the post-meiotic defect patients. This group would be predicted to have a high chance of mTESE success.
[0129] In summary, the methods described herein has the potential to address a wide range of male-infertility issues, including determining the probability that a NOA individual will achieve fertility with the mTESE procedure. Example 4 - The MSA assay predicts mTESE success
[0130] NOA subjects (N=16) were classified into 3 groups (i) pre-meiotic / meiotic block, (ii) post-meiotic block, and (iii) partial defect (the latter of which includes a partial defect in any stage of spermatogenesis) based on their profile of stage-specific markers (FIG. 7). The mTESE procedure was later performed on these subjects and those in which testicular sperm were identified were scored as “successful mTESE.” NOA subjects with a post-meiotic block or a partial progression defect (at any stage) would be predicted to have some testicular sperm or spermatids and thus have a positive mTESE outcome. In contrast. NOA subjects with a pre-meiotic or meiotic block in spermatogenesis would be predicted to produce no or few sperm and thus have a negative mTESE outcome. The results matched these predictions (FIG. 7)
Claims
WHAT IS CLAIMED IS:
1. A method of semen analysis, the method comprising: a) measuring a sperm content in a semen sample obtained from a subject; and b) if the subject has a few or no sperm, determining a stage of a germ cell in the semen sample by measuring the expression level of one or more stage-specific genes or proteins in the germ cell.
2. The method of claim 1, wherein the determining comprises measuring ribonucleic acid molecule (RNA) expression of the one or more cell stage-specific genes in the germ cell.
3. The method of claim 1 or 2, wherein the measuring of the RNA expression level comprises performing polymerase chain reaction (PCR).
4. The method of claim 3, wherein the PCR comprises quantitative polymerase chain reaction (qPCR), TaqMan probe analysis, reverse transcription PCR (rtPCR), or any combinations thereof.
5. The method of claim 1, wherein the measuring of the protein expression level comprises using flow cytometry or ELISA.
6. The method of any one of claims 1-5, wherein the subject is a human male subject.
7. The method of claim 6, wherein the method further comprises diagnosing the human male subject with a condition.
8. The method of claim 7, wherein the condition comprises fertility after vasectomy reversal, suppression of fertility due to male contraceptive use, spermatogenesis status after fertility treatment (such as with gonadotropins or retinoic acid derivatives), spermatogenesis status prior to chemotherapy, naturally-occurring infertility, or a naturally-occurring spermatogenic defects.
9. The method of claim 8, wherein the naturally-occurring spermatogenic defects comprise azoospermia, oligospermia, asthenozoospermia. teratozoospermia, or any combinations thereof.
10. The method of any one of claims 1-9, wherein the method further comprises predicting the presence or absence of immature germ cells or sperm in a testis of the subj ect.
11. The method of any one of claims 1-10, further comprising recommending or performing an action based on the semen analysis.
12. The method of claim 11. wherein the action comprises testicular sperm extraction (TESE) or microdissection testicular sperm extraction (mTESE).
13. The method of claim 12, wherein if the subject is predicted to have sperm in the testis and is diagnosed with infertility, the action comprises generating extracted sperm.
14. The method of claim 13, wherein the action further comprises injecting the extracted sperm into an egg by performing intra-cytoplasmic sperm injection (ICSI).
15. The method of claim 12. wherein if the subject is predicted to have elongated spermatids in the testis and is diagnosed with infertility, the action comprises extracting one or more elongated spermatids from the testis of the subject, thereby generating extracted elongated spermatids.
16. The method of claim 15, wherein the action further comprises injecting the extracted elongated spermatids into an egg by performing elongated spermatid injection (ELSI).
17. The method of claim 12, wherein if the subject is predicted to have round spermatids in the testis and is diagnosed with infertility, the action comprises extracting one or more round spermatids from the testis of the subject, thereby generating extracted round spermatids.
18. The method of claim 17, wherein the action further comprises injecting the extracted round spermatids into an egg by performing round spermatid injection (ROSI).
19. The method of claim 10, wherein an immature germ cell comprises an elongated spermatid.
20. The method of claim 10, wherein an immature germ cell comprises around spermatid.
21. The method of claim 10, wherein an immature germ cell comprises a spermatocyte.
22. The method of claim 10, wherein an immature germ cell comprises spermatogonia.
23. The method of any one of claims 1-22, wherein the one or more stage-specific genes are selected from:UCHL1. C19ORF81, PPP1R36, DMRT1, DNMT1. DAZ, DAZL. ID4, KIT, CTCFL. PNMA5, UTFI, GFRAI, PLPPR3, PIWIL4, FSD1, DMCI, SPO11, OVOS2, TEX12, SYCP1, SDF2L1, DMRTB1, MAGEA4, LIN7B, HMGA1, ZNF428, LMO4, RGMA, ACRC, KLHL15, CCND1, MAGEB2, TCF3. CTSL, TM2D1, PABPC4, ZPBP2, ZPBP, SPAG6, SPEM1, SPEM2, TSSK3, TSSK6, DNAH5, DNAH7, SIRT1, PIWIL3, CHD5, C17ORF98, LRRC3B. IAPP, HDAC11. HBB, FSCN3. CAMK4, PRM1, PRM2, TNP1, TNP2, AURKA, GJA8, MUC12, MROH9, LRRC74B, THAP10, PLCHI, TPRG1, OXCT2, DDX4, CCT2, MAP7D2, RMB46, SMC3. STMN1, TUBA3C . CCDC34, DCDC2C, CDHR2, FAM187B. SPPL2C, KRT15, TEX37, FAM71B, VIM. 80X9, VWF, LCN3, CD45, GAPDH, HRPT1, PGKL PPIA, RPL13A, RPS29, TBP, RPL19, or any combination thereof.
24. The method of claim 23, wherein one or more of the stage-specific genes expressed in spermatogonia comprise UCHL1, C19ORF8L PPP1R36, DMRT1, DMRTB1, DAZ, DAZL. ID4, KIT, CTCFL, PNMA5, UTFI, GFRA1, PLPPR3, PIWIL4, FSD1, MAGEA4, LIN7B, HMGA1, SDF2L1, TM2D1, ZNF428, LMO4, RGMA, ACRC, KLHL15, CCND1, MAGEB2, and TCF3.
25. The method of claim 23. wherein one or more of the stage-specific genes expressed in spermatocytes comprise DMC1, DNMT1, SPO11, CTSL, TM2D1, OVOS2, TEX12, SYCP1. SDF2L1, PABPC4, ZPBP, ZPBP2. and SPAG6.
26. The method of claim 23. wherein one or more of the stage-specific genes expressed spermatids comprise ZPBP2, ZPBP, SPAG6, SPEM1, SPEM2, TSSK3, TSSK6, DNAH5,DNAH7, SIRT1, PIWIL3, CHD5, C17ORF98, LRRC3B, IAPP, HDAC11, HBB, FSCN3, CAMK4, PRM1, PRM2, TNP1, TNP2, AURKA, GJA8, NUTM1. MUC12. MROH9.LRRC74B, THAP10, PLCHI. TPRG1, and 0XCT2.
27. A non-invasive method for determining whether a male human subject is likely to benefit from a testicular sperm extraction procedure, round spermatid injection, elongated spermatid injection for conception or fertilization, wherein the method comprises the method of any one of claims 1-26.
28. The method of claim 27, further comprising non-invasive detection of fertility defects, detection of spermatogenic changes in response to extrinsic treatments, or both.
Citation Information
Patent Citations
Methods and compositions for detecting spermatozoa or semen in a sample
US8021852B2
